Prestige Biopharma Innovative Discovery Centre

Prestige Biopharma Innovative Discovery Centre (IDC) is the primary research and development hub for Prestige Biopharma, located in Busan, South Korea. The center specializes in the discovery of first-in-class antibody therapeutics and the development of a robust pipeline of high-quality biosimilars. Its lead innovative program, ulenistamab (PBP1510), targets the PAUF protein for the treatment of pancreatic cancer and has received orphan drug designations from the FDA, EMA, and MFDS. The IDC utilizes advanced antibody engineering and high-throughput screening technologies to address significant unmet medical needs in oncology and immunology. By integrating discovery research with clinical development strategies, the center aims to accelerate the delivery of innovative biologics to global markets.